Jun Zhang MD PhD

Oncology•Kansas City, KS

Thoracic Cancer

Associate Professor

Join to View Full Profile

3901 Rainbow BlvdDivision Of Medical Oncology, Department Of Internal MedicineKansas City, KS 66160
Phone+1 913-588-2825

Education & Training

Emory University School of MedicineFellowship, Hematology and Medical Oncology, 2012
One Brooklyn Health System - Kingsbrook Jewish Medical CenterResidency, Internal Medicine, 2009 - 2012
University of California San Francisco School of MedicinePost-Doctoral Fellowship, 2006 - 2009
Dana-Farber Cancer Institute, Harvard Medical SchoolPost-Doctoral Fellowship, 2006 - 2006
Lousiana State University Health Science CenterPhD, Cancer Biology, Cellular Biology & Anatomy, 2000 - 2004
Hunan Medical UniversityClass of 1995

Certifications & Licensure

MO State Medical License 2021 - 2026
KS State Medical License 2019 - 2025
IA State Medical License 2015 - 2021
American Board of Internal Medicine Medical Oncology

Clinical Trials

Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients Start of enrollment: 2021 Apr 12
Recruiting
Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy Start of enrollment: 2021 Sep 14
Recruiting
Phase 2
Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC Start of enrollment: 2022 Jul 21
Recruiting
Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC) Start of enrollment: 2020 Jul 29
Recruiting
This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. Start of enrollment: 2019 Nov 05
Terminated
Phase 2
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 Start of enrollment: 2019 Jan 15
RECRUITING
PHASE1, PHASE2
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation Start of enrollment: 2021 Feb 23
ACTIVE_NOT_RECRUITING
PHASE3
Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy Start of enrollment: 2020 Sep 11
Active, not recruiting
Phase 3
Roles: Contact
Rinatabart Sesutecan (Rina-S) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) Start of enrollment: 2022 Dec 07
RECRUITING
PHASE1, PHASE2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials.
Benjamin J Solomon, Daniel S W Tan, Gilberto de Castro Junior, Manuel Cobo, Marina Chiara Garassino
Cancer Research Communications. 2025-03-21
Tarlatamab Rechallenge After Grade 3 Cytokine Release Syndrome Leading to Tumor Regression in Two Weeks and Reopening of a Collapsed Lung: A Case Report.
Timothy Schieber, Prakash Neupane, Haoran Li, Chao Huang, Jun Zhang
Clinical Lung Cancer. 2025-03-01
DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer.
Christine M Bestvina, Jared H L Hara, Theodore Karrison, Benjamen Bowar, Janet Chin
Clinical Lung Cancer. 2024-12-01

Professional Memberships

American Society of Clinical Oncology - ASCO
Member